Biomay, a global leader in allergy immunotherapy, announced today that a second Phase IIb study (clinicaltrials.gov identifier NCT02643641) has been successfully completed with its third generation grass pollen allergy vaccine BM32. The study was designed to demonstrate the optimal dose regimen to induce an allergen-specific IgG immune response. Correlation of the immunological effects with the alleviation of allergy symptoms in the subsequent grass pollen season was another important objective of the trial.
↧